Peter Ansell
YOU?
Author Swipe
View article: Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous <i>EGFR</i> -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous <i>EGFR</i> -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial Open
PURPOSE Telisotuzumab vedotin (Teliso-V) is a c-Met–directed antibody-drug conjugate with a monomethyl auristatin E cytotoxic payload. The phase II LUMINOSITY trial (ClinicalTrials.gov identifier: NCT03539536 ) aimed to identify the optima…
View article: Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over
Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over Open
HRD frequency was similar in participants aged < 70 and ≥ 70 years (35% vs 31%) when the contribution of gBRCA was excluded; rates of sBRCA PVs were also similar (8% v 10%), thus underscoring the importance of HRD and BRCA testing at diagn…
View article: Table S1 from Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors
Table S1 from Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors Open
Additional details for TEAEs and TRAEs for all doses in the escalation cohort
View article: Table S1 from Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors
Table S1 from Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors Open
Additional details for TEAEs and TRAEs for all doses in the escalation cohort
View article: Table S2 from Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors
Table S2 from Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors Open
Additional details for MET-amplified patients with one or more postbaseline tumor assessment (n=9).
View article: Data from Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors
Data from Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors Open
This first-in-human phase I study evaluated the pharmacokinetics, safety, and preliminary efficacy of telisotuzumab, formerly called ABT-700, an antagonistic antibody directed against c-Met. For dose escalation (3+3 design), 3 to 6 patient…
View article: Figure S1 from Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors
Figure S1 from Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors Open
Progression-free survival in MET-amplified patients
View article: Table S3 from Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors
Table S3 from Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors Open
FISH analysis or ctDNA analysis for MET amplification was performed on enrolled patients (N=45).
View article: Data from Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors
Data from Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors Open
This first-in-human phase I study evaluated the pharmacokinetics, safety, and preliminary efficacy of telisotuzumab, formerly called ABT-700, an antagonistic antibody directed against c-Met. For dose escalation (3+3 design), 3 to 6 patient…
View article: Table S2 from Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors
Table S2 from Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors Open
Additional details for MET-amplified patients with one or more postbaseline tumor assessment (n=9).
View article: Figure S2 from Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors
Figure S2 from Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors Open
CEA response over time in a 47-year-old patient with GEC responding to telisotuzumab
View article: Figure S2 from Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors
Figure S2 from Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors Open
CEA response over time in a 47-year-old patient with GEC responding to telisotuzumab
View article: Table S3 from Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors
Table S3 from Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors Open
FISH analysis or ctDNA analysis for MET amplification was performed on enrolled patients (N=45).
View article: Table S4 from Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors
Table S4 from Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors Open
Additional details on TEAEs for all doses in the combination therapy cohort
View article: Table S4 from Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors
Table S4 from Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors Open
Additional details on TEAEs for all doses in the combination therapy cohort
View article: Figure S1 from Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors
Figure S1 from Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors Open
Progression-free survival in MET-amplified patients
View article: Data from Comparison of Biomarker Assays for <i>EGFR</i>: Implications for Precision Medicine in Patients with Glioblastoma
Data from Comparison of Biomarker Assays for <i>EGFR</i>: Implications for Precision Medicine in Patients with Glioblastoma Open
Purpose:Patients with glioblastoma (GBM) have a poor prognosis and are in desperate need of better therapies. As therapeutic decisions are increasingly guided by biomarkers, and EGFR abnormalities are common in GBM, thus representing a pot…
View article: Supplemental Tables and Figures from Comparison of Biomarker Assays for <i>EGFR</i>: Implications for Precision Medicine in Patients with Glioblastoma
Supplemental Tables and Figures from Comparison of Biomarker Assays for <i>EGFR</i>: Implications for Precision Medicine in Patients with Glioblastoma Open
Supplementary Table S2. Concordance of FISH and WES results. Supplementary Table S3. Point mutations identified in EGFR. Supplementary Table S4. Concordance of FISH and RT-PCR results. Supplementary Table S5. Concordance of FISH and RNAseq…
View article: Supplemental Materials from Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer
Supplemental Materials from Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer Open
Supplemental Table 1. Demographics and baseline characteristics by histology: squamous cell Supplemental Table 2. Demographics and baseline characteristics by histology: non-squamous cell Supplemental Table 3. Mean {plus minus} SD pharmaco…
View article: Data from Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer
Data from Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer Open
Purpose: PARP plays an important role in DNA repair. Veliparib, a PARP inhibitor, enhances the efficacy of platinum compounds and has been safely combined with carboplatin and paclitaxel. The primary endpoint of this phase II trial determi…
View article: Supplementary Table S1 from Comparison of Biomarker Assays for <i>EGFR</i>: Implications for Precision Medicine in Patients with Glioblastoma
Supplementary Table S1 from Comparison of Biomarker Assays for <i>EGFR</i>: Implications for Precision Medicine in Patients with Glioblastoma Open
Supplementary Table S1. Data for tumor samples and all assays performed.
View article: Supplemental Tables and Figures from Comparison of Biomarker Assays for <i>EGFR</i>: Implications for Precision Medicine in Patients with Glioblastoma
Supplemental Tables and Figures from Comparison of Biomarker Assays for <i>EGFR</i>: Implications for Precision Medicine in Patients with Glioblastoma Open
Supplementary Table S2. Concordance of FISH and WES results. Supplementary Table S3. Point mutations identified in EGFR. Supplementary Table S4. Concordance of FISH and RT-PCR results. Supplementary Table S5. Concordance of FISH and RNAseq…
View article: Supplementary Table S1 from Comparison of Biomarker Assays for <i>EGFR</i>: Implications for Precision Medicine in Patients with Glioblastoma
Supplementary Table S1 from Comparison of Biomarker Assays for <i>EGFR</i>: Implications for Precision Medicine in Patients with Glioblastoma Open
Supplementary Table S1. Data for tumor samples and all assays performed.
View article: Data from Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer
Data from Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer Open
Purpose: PARP plays an important role in DNA repair. Veliparib, a PARP inhibitor, enhances the efficacy of platinum compounds and has been safely combined with carboplatin and paclitaxel. The primary endpoint of this phase II trial determi…
View article: Data from Comparison of Biomarker Assays for <i>EGFR</i>: Implications for Precision Medicine in Patients with Glioblastoma
Data from Comparison of Biomarker Assays for <i>EGFR</i>: Implications for Precision Medicine in Patients with Glioblastoma Open
Purpose:Patients with glioblastoma (GBM) have a poor prognosis and are in desperate need of better therapies. As therapeutic decisions are increasingly guided by biomarkers, and EGFR abnormalities are common in GBM, thus representing a pot…
View article: Supplemental Materials from Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer
Supplemental Materials from Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer Open
Supplemental Table 1. Demographics and baseline characteristics by histology: squamous cell Supplemental Table 2. Demographics and baseline characteristics by histology: non-squamous cell Supplemental Table 3. Mean {plus minus} SD pharmaco…
View article: Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma
Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma Open
Background Serclutamab talirine (Ser-T, formerly ABBV-321) is an antibody-drug conjugate consisting of an antibody (AM-1-ABT-806) directed against activated epidermal growth factor receptor (EGFR) and a pyrrolobenzodiazepine dimer. We inve…